New research shows that cystic fibrosis causes a specific defect in the lungs’ mucus process.
Vertex Pharmaceuticals Inc says results from two Phase 3 studies of its lumacaftor-ivacaftor drug combination showed statistically significant improvements in lung function (ppFEV1) in cystic fibrosis patients (12+) who have two copies of the F508del mutation.
OligoG, a breakthrough medication derived from Norwegian seaweed, may be an effective treatment for cystic fibrosis, according to research that suggests it helps to break down the thick, sticky mucus that characterizes CF.
As the number of chronic lung patients continues to grow, today’s aerosol therapy products are providing high-quality, cost-efficient medication delivery.
Boosting a key immune process called autophagy with interferon gamma (IFN-γ) could help clear a lethal bacterial infection in cystic fibrosis, a new study suggests.
Electromed Inc has joined in the launch of a new children’s book, Healthy Choices, Happy Kids: Making Good Choices with Everyday Care, and will include a free copy of the book with all SmartVest shipments for newly prescribed patients 10 years old and younger (while supplies last).
An antimicrobial peptide produced by human immune cells can promote mutations in P. aeruginosa bacterium, a common cause of death in cystic fibrosis patients.
Initiatives across the country are expanding access to quality spirometry, a key component in the proper diagnosis and treatment of respiratory conditions like COPD and asthma.
Diacetyl, a toxic molecule found in microwave popcorn flavoring and linked to lung injuries in factory workers, might play an important role in microbial lung infections in cystic fibrosis patients.
The FDA has approved a supplemental New Drug Application for Kalydeco (ivacaftor) for use in eight additional mutations that cause cystic fibrosis.